Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medipharm Labs Corp (OP:MEDIF)

0.0451 -0.0034 (-7.01%)
Delayed Quote Updated: 10:03 AM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medipharm Labs Corp

< Previous 1 2 3 4 5 6 Next >
News headline image
MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee Facility
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo’s Arguments and Director Slate
ISS concludes that Apollo “has not presented a compelling case for change” 
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MEDIF Stock Earnings: MediPharm Labs Reported Results for Q2 2024 ↗
MediPharm Labs just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
MEDIF Stock Earnings: MediPharm Labs Reported Results for Q1 2024 ↗
MediPharm Labs just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
MEDIF Stock Earnings: MediPharm Labs Reported Results for Q4 2023 ↗
MediPharm Labs just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital
From Apollo Technology Capital Corporation
Via GlobeNewswire
News headline image
MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Alleged Securities Fraud at MediPharm Labs Says Apollo Capital
From Apollo Technology Capital Corporation
Via GlobeNewswire
News headline image
MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck’s Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma
From Apollo Technology Capital Corporation
Via GlobeNewswire
News headline image
MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Apollo Capital Comments on MediPharm Labs’ Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual Meeting
From Apollo Technology Capital Corporation
Via GlobeNewswire
News headline image
MediPharm Achieves Key Milestone Toward $4.5 Million Cash Sale of Hope Facility, On Track to Close in June
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Alerts Shareholders to Allegations Made Against Regan McGee in Multiple Litigation Filings
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
This Week In Cannabis: Trump Policy Updates, Corporate Moves, Regulatory Shifts And Product Innovations ↗
This week in cannabis: major mergers, innovative launches, key regulatory updates & leadership changes drive industry transformation. 
Via Benzinga
Topics Government
News headline image
CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth ↗
CBD-based pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Thursday its third quarter financial results for the three months ended Sept. 30, 2024."Q3 2024... 
Via Benzinga
News headline image
MediPharm Q2 Loss Narrows, Adjusted EBITDA Climbs As Gross Profit Improves Nearly 300% YoY ↗
Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday financial results for the second quarter ended June 30, 2024, revealing an... 
Via Benzinga
Topics Cannabis
News headline image
The Canadian Cannabis Report- Monday, Aug 12 ↗
The past, present and future of the Canadian cannabis sector. 
Via Talk Markets
Topics Cannabis
News headline image
This Cannabis Co With Significant Growth Potential And Other Hot Weed Stocks Soon To Report Earnings, What Investors Need To Know Now ↗
Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF), a cannabis operator with vertical operations in Arizona and Ohio, said it will release its financial results for the second quarter ended June 30, 2024,... 
Via Benzinga
Topics Cannabis
News headline image
Executive Changes In Cannabis Industry You Should Know About, New Appointments & More ↗
Shareholders of four cannabis companies held their respective annual meetings, electing nominees as board directors.Sandy Li, who has been serving at cannabis edibles producer Wana Brands since 2022 as... 
Via Benzinga
Topics Cannabis
News headline image
Cannabinoids-Focused MediPharm Boasts This Advanced Medical Cannabis Delivery Method ↗
Cannabinoids-based pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Thursday that it has entered into a licensing agreement with Remidose Aerosols Inc. to... 
Via Benzinga
Topics Cannabis
News headline image
Cannabinoids-Focused Pharma Company, MediPharm, Sees Higher Q1 Revenue, CFO Touts 'Strong Financial Position' ↗
 
Via Benzinga
News headline image
The Canadian Cannabis Report - Monday, April 22 ↗
The past, present and future of the Canadian cannabis sector, based on the performanceof the MCCCI, which is a proprietary index of 14 stocks. 
Via Talk Markets
Topics Cannabis
News headline image
This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses ↗
Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday its financial results for the full year and three months ended Dec. 31,... 
Via Benzinga
News headline image
The Canadian Cannabis Report - Monday, March 25 ↗
The past, present and future of the Canadian cannabis sector based on the performance of the MCCCI, which is a proprietary index of 14 stocks 
Via Talk Markets
Topics Cannabis
News headline image
Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil ↗
Canada's MediPharm Labs has received a GMP certification from the Brazilian governing body, ANVISA. The approval allows for the production of active pharmaceutical ingredients (APIs) and end products... 
Via Benzinga
Topics Cannabis
News headline image
Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024 ↗
This month, the Indigenous Cannabis Industry Association held its first Indigenous Cannabis Regulators roundtable, bringing together Indigenous Cannabis Regulators from Tribal Nations and... 
Via Benzinga
Topics Cannabis
News headline image
MediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial Report ↗
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) reported its financial results for the three months ended September 30, 2023, with a revenue of C$8.5 million. This reflects a decrease of... 
Via Benzinga
News headline image
New Cannabis Products Energize Global Health & Wellness Market, Including Australia ↗
In the ever-evolving world of cannabis products, innovation is the name of the game for those in search of health and wellness solutions. 
Via Benzinga
Topics Cannabis
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.